nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide
|
Cross, Charlotte |
|
|
27 |
4 |
|
artikel |
2 |
A Comparative Study on Physicochemical and Analytical Characterizations of Doxil® and its Generic Drug Products
|
Eneli, Adaeze |
|
|
27 |
4 |
|
artikel |
3 |
An Ocular Exposure Prediction for Topical Atropine in Human Using Physiologically Based Pharmacokinetic Modeling
|
Zheng, Aole |
|
|
27 |
4 |
|
artikel |
4 |
Application of Real-World Evidence to Support FDA Regulatory Decision Making
|
Khaowroongrueng, Vipada |
|
|
27 |
4 |
|
artikel |
5 |
Assessing the Impact of Multiple Imputation Algorithms on Pharmacokinetic Model Performance: A Simulation-Based Study
|
Duflot, Thomas |
|
|
27 |
4 |
|
artikel |
6 |
Automation of Anti-Drug Antibody Enrichment Using Streptavidin PhyTip® Columns for Sample Pretreatment in an Immunogenicity Assay
|
Luong, Michael |
|
|
27 |
4 |
|
artikel |
7 |
Correction: Establishing Clinically Relevant Specifications for Carbamazepine Tablets Using Physiologically Based Pharmacokinetic Modeling
|
Wang, Xiaofeng |
|
|
27 |
4 |
|
artikel |
8 |
Correction: Nitrosamines Risk Assessment for Biopharmaceutics Classifcation System Class IV Molecule Containing Immediate Release Products: Use of In-Silico Prediction Tools and Physiologically Based Pharmacokinetic Modeling
|
Kollipara, Sivacharan |
|
|
27 |
4 |
|
artikel |
9 |
Dose Optimization of ClpP Agonists Using an In Vitro Microfluidic Perfusion Platform and In Silico Pharmacokinetic-Pharmacodynamic Modeling
|
Bucher, Ronald W. |
|
|
27 |
4 |
|
artikel |
10 |
Establishing Clinically Relevant Specifications for Carbamazepine Tablets Using Physiologically Based Pharmacokinetic Modeling
|
Wang, Xiaofeng |
|
|
27 |
4 |
|
artikel |
11 |
Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative Review
|
Mao, Bingyu |
|
|
27 |
4 |
|
artikel |
12 |
Factors Impacting the Immunogenicity of Etrolizumab & Clinical Consequences
|
Sperinde, Gizette |
|
|
27 |
4 |
|
artikel |
13 |
Generating Realistic Albumin Concentrations in Virtual Subjects Across A Spectrum of Renal Function to Account for Variability in Protein Binding Within PBPK Models
|
Hu, Yuming |
|
|
27 |
4 |
|
artikel |
14 |
IFN-γ/IL-2 Double-Color FluoroSpot Assay for Monitoring Human Primary T Cell Activation: Validation, Inter-Laboratory Comparison, and Recommendations for Clinical Studies
|
Mauthe, Alexandra |
|
|
27 |
4 |
|
artikel |
15 |
Improvement of Drug Release from an Aptamer Drug Conjugate Using Reductive-sensitive Linkers for Tumor-targeted Drug Delivery
|
Wu, You |
|
|
27 |
4 |
|
artikel |
16 |
Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments
|
Gong, Jue |
|
|
27 |
4 |
|
artikel |
17 |
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy
|
Chen, Ping |
|
|
27 |
4 |
|
artikel |
18 |
Model-informed Drug Development (MIDD) Approach to Support Biopharmaceutical Development of Iberdomide
|
Sychterz, Caroline |
|
|
27 |
4 |
|
artikel |
19 |
Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab
|
Zhao, Yue |
|
|
27 |
4 |
|
artikel |
20 |
Nitrosamines Risk Assessment for Biopharmaceutics Classification System Class IV Molecule Containing Immediate Release Products: Use of In-Silico Prediction Tools and Physiologically Based Pharmacokinetic Modeling
|
Kollipara, Sivacharan |
|
|
27 |
4 |
|
artikel |
21 |
Physiologically Based Modeling of Cefoxitin, Cefazolin, and Piperacillin Pharmacokinetics in Obese and Lean Rats
|
Sheng, Yi-Hua |
|
|
27 |
4 |
|
artikel |
22 |
Publisher Correction: Generating Realistic Albumin Concentrations in Virtual Subjects Across A Spectrum of Renal Function to Account for Variability in Protein Binding Within PBPK Models
|
Hu, Yuming |
|
|
27 |
4 |
|
artikel |
23 |
Publisher Correction: Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
|
Cleary, Yumi |
|
|
27 |
4 |
|
artikel |
24 |
Recommendation of IV Dose Preparation Practices Using Closed System Transfer Devices (CSTD) for Accurate Dosing
|
Liu, Qunhui |
|
|
27 |
4 |
|
artikel |
25 |
Removal of Excipients from Drug Product may Impact Antibody Characterization of Monoclonal Antibodies
|
Krishna, Kunal |
|
|
27 |
4 |
|
artikel |
26 |
Rethinking Pharmaceutical Industry with Quality by Design: Application in Research, Development, Manufacturing, and Quality Assurance
|
Duarte, Joana Galvão |
|
|
27 |
4 |
|
artikel |
27 |
Short-Term Immunosuppression in Rats Induces Prolonged Immune Tolerance Towards a Human Monoclonal Antibody, Erenumab
|
Gupta, Paridhi |
|
|
27 |
4 |
|
artikel |
28 |
Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
|
Cleary, Yumi |
|
|
27 |
4 |
|
artikel |
29 |
Social Inequality and Antimicrobial Resistance: An Interconnected Global Problem
|
Vitiello, Antonio |
|
|
27 |
4 |
|
artikel |
30 |
The Reference-Corrected Visual Predictive Check: A More Intuitive Diagnostic for Non-Linear Mixed Effects Models
|
Ibrahim, Moustafa M. A. |
|
|
27 |
4 |
|
artikel |
31 |
The 100th Monoclonal Antibody Product is Approved in Japan
|
Hariu, Aya |
|
|
27 |
4 |
|
artikel |
32 |
The Use of Surrogate Matrix for Calibrators in the Analysis of Dried Blood Samples – A Feasibility Study
|
Lee, Dong Hun |
|
|
27 |
4 |
|
artikel |
33 |
TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery
|
Misra, Bishal |
|
|
27 |
4 |
|
artikel |